SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001564590-21-018359
Filing Date
2021-04-09
Accepted
2021-04-09 17:05:28
Documents
10

Document Format Files

Seq Description Document Type Size
1 S-3 srne-s3.htm S-3 383262
2 EX-4.18 srne-ex418_49.htm EX-4.18 151405
3 EX-4.19 srne-ex419_50.htm EX-4.19 194125
4 EX-5.1 srne-ex51_69.htm EX-5.1 23614
5 EX-23.1 srne-ex231_16.htm EX-23.1 2824
6 EX-23.2 srne-ex232_17.htm EX-23.2 2998
7 GRAPHIC gp3wqw1uz0wl000001.jpg GRAPHIC 3210
8 GRAPHIC gp3wqw1uz0wl000002.jpg GRAPHIC 3210
9 GRAPHIC gmd3wuxmh4bv000001.jpg GRAPHIC 11200
10 GRAPHIC gmd3wuxmh4bv000002.jpg GRAPHIC 17892
  Complete submission text file 0001564590-21-018359.txt   808815
Mailing Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121
Business Address 4955 DIRECTORS PLACE SAN DIEGO CA 92121 858-203-4100
Sorrento Therapeutics, Inc. (Filer) CIK: 0000850261 (see all company filings)

IRS No.: 330344842 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-255165 | Film No.: 21818476
SIC: 2836 Biological Products, (No Diagnostic Substances)